998 related articles for article (PubMed ID: 35704649)
1. COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.
Barchuk A; Skougarevskiy D; Kouprianov A; Shirokov D; Dudkina O; Tursun-Zade R; Sergeeva M; Tychkova V; Komissarov A; Zheltukhina A; Lioznov D; Isaev A; Pomerantseva E; Zhikrivetskaya S; Sofronova Y; Blagodatskikh K; Titaev K; Barabanova L; Danilenko D
PLoS One; 2022; 17(6):e0266945. PubMed ID: 35704649
[TBL] [Abstract][Full Text] [Related]
2. Seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia: a population-based study.
Barchuk A; Skougarevskiy D; Titaev K; Shirokov D; Raskina Y; Novkunkskaya A; Talantov P; Isaev A; Pomerantseva E; Zhikrivetskaya S; Barabanova L; Volkov V
Sci Rep; 2021 Jun; 11(1):12930. PubMed ID: 34155259
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the performance of SARS--CoV--2 antibody assays for a longitudinal population-based study of COVID--19 spread in St. Petersburg, Russia.
Barchuk A; Shirokov D; Sergeeva M; Tursun Zade R; Dudkina O; Tychkova V; Barabanova L; Skougarevskiy D; Danilenko D
J Med Virol; 2021 Oct; 93(10):5846-5852. PubMed ID: 34081328
[TBL] [Abstract][Full Text] [Related]
4. Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis.
COVID-19 Cumulative Infection Collaborators
Lancet; 2022 Jun; 399(10344):2351-2380. PubMed ID: 35405084
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 vaccines effectiveness against symptomatic SARS-CoV-2 during Delta variant surge: a preliminary assessment from a case-control study in St. Petersburg, Russia.
Barchuk A; Bulina A; Cherkashin M; Berezina N; Rakova T; Kuplevatskaya D; Stanevich O; Skougarevskiy D; Okhotin A
BMC Public Health; 2022 Sep; 22(1):1803. PubMed ID: 36138385
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal Randomized Cohort Study of SARS-CoV-2 Antibody Seroprevalence in the St. Petersburg Population.
Smirnov VS; Lyalina LV; Milichkina AM; Khamitova IV; Zueva EV; Ivanov VA; Zaguzov VS; Totolian AA
Viruses; 2022 Apr; 14(5):. PubMed ID: 35632653
[TBL] [Abstract][Full Text] [Related]
7. Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves.
Boon SS; Wong MCS; Ng RWY; Leung DTM; Chen Z; Lai CKC; Ho WCS; Huang J; Wong BKC; Fung KSC; Chan PKS
JAMA Netw Open; 2021 Nov; 4(11):e2132923. PubMed ID: 34779848
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 Seroprevalence Structure of the Russian Population during the COVID-19 Pandemic.
Popova AY; Smirnov VS; Andreeva EE; Babura EA; Balakhonov SV; Bashketova NS; Bugorkova SA; Bulanov MV; Valeullina NN; Vetrov VV; Goryaev DV; Detkovskaya TN; Ezhlova EB; Zaitseva NN; Istorik OA; Kovalchuk IV; Kozlovskikh DN; Kombarova SY; Kurganova OP; Lomovtsev AE; Lukicheva LA; Lyalina LV; Melnikova AA; Mikailova OM; Noskov AK; Noskova LN; Oglezneva EE; Osmolovskaya TP; Patyashina MA; Penkovskaya NA; Samoilova LV; Stepanova TF; Trotsenko OE; Totolian AA
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452512
[TBL] [Abstract][Full Text] [Related]
9. Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic.
Tunheim G; Rø GØI; Tran T; Kran AB; Andersen JT; Vaage EB; Kolderup A; Vaage JT; Lund-Johansen F; Hungnes O
Influenza Other Respir Viruses; 2022 Mar; 16(2):204-212. PubMed ID: 34751488
[TBL] [Abstract][Full Text] [Related]
10. Variation in the COVID-19 infection-fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis.
COVID-19 Forecasting Team
Lancet; 2022 Apr; 399(10334):1469-1488. PubMed ID: 35219376
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
[TBL] [Abstract][Full Text] [Related]
12. Estimates and Determinants of SARS-Cov-2 Seroprevalence and Infection Fatality Ratio Using Latent Class Analysis: The Population-Based Tirschenreuth Study in the Hardest-Hit German County in Spring 2020.
Wagner R; Peterhoff D; Beileke S; Günther F; Berr M; Einhauser S; Schütz A; Niller HH; Steininger P; Knöll A; Tenbusch M; Maier C; Korn K; Stark KJ; Gessner A; Burkhardt R; Kabesch M; Schedl H; Küchenhoff H; Pfahlberg AB; Heid IM; Gefeller O; Überla K
Viruses; 2021 Jun; 13(6):. PubMed ID: 34200766
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey.
Hoballah A; El Haidari R; Siblany G; Abdel Sater F; Mansour S; Hassan H; Abou-Abbas L
BMC Infect Dis; 2022 Jan; 22(1):42. PubMed ID: 35012464
[TBL] [Abstract][Full Text] [Related]
14. Enhanced surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic.
Dickson E; Palmateer NE; Murray J; Robertson C; Waugh C; Wallace LA; Mathie L; Heatlie K; Mavin S; Gousias P; Von Wissman B; Goldberg DJ; McAuley A
Public Health; 2021 Jan; 190():132-134. PubMed ID: 33453689
[TBL] [Abstract][Full Text] [Related]
15. Estimation of US SARS-CoV-2 Infections, Symptomatic Infections, Hospitalizations, and Deaths Using Seroprevalence Surveys.
Angulo FJ; Finelli L; Swerdlow DL
JAMA Netw Open; 2021 Jan; 4(1):e2033706. PubMed ID: 33399860
[TBL] [Abstract][Full Text] [Related]
16. Gam-COVID-Vac, EpiVacCorona, and CoviVac effectiveness against lung injury during Delta and Omicron variant surges in St. Petersburg, Russia: a test-negative case-control study.
Barchuk A; Bulina A; Cherkashin M; Berezina N; Rakova T; Kuplevatskaya D; Skougarevskiy D; Okhotin A
Respir Res; 2022 Oct; 23(1):276. PubMed ID: 36217139
[TBL] [Abstract][Full Text] [Related]
17. Epidemiological Features of COVID-19 in Northwest Russia in 2021.
Gladkikh A; Dedkov V; Sharova A; Klyuchnikova E; Sbarzaglia V; Kanaeva O; Arbuzova T; Tsyganova N; Popova A; Ramsay E; Totolian A
Viruses; 2022 Apr; 14(5):. PubMed ID: 35632673
[TBL] [Abstract][Full Text] [Related]
18. High seroprevalence of SARS-CoV-2 in Burkina-Faso, Ghana and Madagascar in 2021: a population-based study.
Struck NS; Lorenz E; Deschermeier C; Eibach D; Kettenbeil J; Loag W; Brieger SA; Ginsbach AM; Obirikorang C; Maiga-Ascofare O; Sarkodie YA; Boham EEA; Adu EA; Asare G; Amoako-Adusei A; Yawson A; Boakye AO; Deke J; Almoustapha NS; Adu-Amoah L; Duah IK; Ouedraogo TA; Boudo V; Rushton B; Ehmen C; Fusco D; Gunga L; Benke D; Höppner Y; Rasolojaona ZT; Rasamoelina T; Rakotoarivelo RA; Rakotozandrindrainy R; Coulibaly B; Sié A; Awuah AA; Amuasi JH; Souares A; May J
BMC Public Health; 2022 Sep; 22(1):1676. PubMed ID: 36064368
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant, and implications for vaccination.
Yang W; Shaman J
medRxiv; 2021 Nov; ():. PubMed ID: 34845460
[TBL] [Abstract][Full Text] [Related]
20. Seroprevalence of SARS-CoV-2 Antibodies Among Children in School and Day Care in Montreal, Canada.
Zinszer K; McKinnon B; Bourque N; Pierce L; Saucier A; Otis A; Cheriet I; Papenburg J; Hamelin MÈ; Charland K; Carbonneau J; Zahreddine M; Savard A; Fortin G; Apostolatos A; Haley N; Ratté N; Laurin I; Nguyen CT; Conrod P; Boivin G; De Serres G; Quach C
JAMA Netw Open; 2021 Nov; 4(11):e2135975. PubMed ID: 34812845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
